MX2009005946A - Combinacion de un inhibidor de desacetilasa de histona y un antimetabolito. - Google Patents
Combinacion de un inhibidor de desacetilasa de histona y un antimetabolito.Info
- Publication number
- MX2009005946A MX2009005946A MX2009005946A MX2009005946A MX2009005946A MX 2009005946 A MX2009005946 A MX 2009005946A MX 2009005946 A MX2009005946 A MX 2009005946A MX 2009005946 A MX2009005946 A MX 2009005946A MX 2009005946 A MX2009005946 A MX 2009005946A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- relates
- aml
- mds
- hdai
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se refiere a una combinación que comprende (a) un inhibidor de desacetilasa de histona (HDAI); y (b) un anti-metabolito, para su uso simultáneo, concurrente, separado, o en secuencia, en especial para utilizarse en el tratamiento de enfermedades proliferativas, más específicamente MDS o AML. La invención también se refiere a composiciones farmacéuticas que comprenden esta combinación, y a un método para el tratamiento de MDS, o AML, en un mamífero, en particular un ser humano, con esta combinación. La presente invención también se refiere además a un paquete o producto comercial que comprende dicha combinación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86838806P | 2006-12-04 | 2006-12-04 | |
| PCT/US2007/024712 WO2008070011A2 (en) | 2006-12-04 | 2007-11-30 | Combination of an hdac inhibitor and an antimetabolite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009005946A true MX2009005946A (es) | 2009-06-17 |
Family
ID=39272127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009005946A MX2009005946A (es) | 2006-12-04 | 2007-11-30 | Combinacion de un inhibidor de desacetilasa de histona y un antimetabolito. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8093220B2 (es) |
| EP (1) | EP2099451B1 (es) |
| JP (3) | JP5784274B2 (es) |
| KR (1) | KR101475538B1 (es) |
| CN (1) | CN101553223A (es) |
| AR (1) | AR064072A1 (es) |
| AU (1) | AU2007328281B2 (es) |
| BR (1) | BRPI0719746A2 (es) |
| CA (1) | CA2670741C (es) |
| CL (1) | CL2007003467A1 (es) |
| EC (1) | ECSP099483A (es) |
| ES (1) | ES2569477T3 (es) |
| GT (1) | GT200900148A (es) |
| IL (1) | IL198638A (es) |
| MA (1) | MA30982B1 (es) |
| MX (1) | MX2009005946A (es) |
| MY (1) | MY148893A (es) |
| NO (1) | NO20092473L (es) |
| PE (1) | PE20081303A1 (es) |
| PL (1) | PL2099451T3 (es) |
| RU (1) | RU2469717C2 (es) |
| TN (1) | TN2009000213A1 (es) |
| TW (1) | TW200831075A (es) |
| WO (1) | WO2008070011A2 (es) |
| ZA (1) | ZA200903041B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2628726A1 (en) * | 2008-03-26 | 2013-08-21 | Novartis AG | Hydroxamate-based inhibitors of deacetylases b |
| WO2010009285A1 (en) * | 2008-07-18 | 2010-01-21 | Novartis Ag | Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome |
| US20110118309A1 (en) * | 2008-07-18 | 2011-05-19 | Peter Wisdom Atadja | Use of hdac inhibitors for the treatment of hodgkin's disease |
| US20110053925A1 (en) * | 2009-08-28 | 2011-03-03 | Novartis Ag | Hydroxamate-Based Inhibitors of Deacetylases |
| PH12012502399A1 (en) * | 2010-06-07 | 2013-02-11 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| AU2011296047A1 (en) * | 2010-09-01 | 2013-03-21 | Novartis Ag | Combination of HDAC inhibitors with thrombocytopenia drugs |
| EP2968282B1 (en) * | 2013-03-12 | 2018-05-09 | Celgene Quanticel Research, Inc. | Histone dementhylase inhibitors |
| CN105960239A (zh) * | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
| CA2961580A1 (en) | 2014-09-17 | 2016-03-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| BR112017019453A2 (pt) | 2015-03-13 | 2018-05-15 | Forma Therapeutics Inc | compostos e composições de alfa-cinamida como inibidores de hdac8 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| MXPA05012464A (es) * | 2003-05-21 | 2006-01-30 | Novartis Ag | Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos. |
-
2007
- 2007-11-30 MY MYPI20091975A patent/MY148893A/en unknown
- 2007-11-30 PL PL07862420T patent/PL2099451T3/pl unknown
- 2007-11-30 MX MX2009005946A patent/MX2009005946A/es active IP Right Grant
- 2007-11-30 KR KR1020097013917A patent/KR101475538B1/ko not_active Expired - Fee Related
- 2007-11-30 AR ARP070105351A patent/AR064072A1/es unknown
- 2007-11-30 CN CNA2007800429689A patent/CN101553223A/zh active Pending
- 2007-11-30 CA CA2670741A patent/CA2670741C/en not_active Expired - Fee Related
- 2007-11-30 EP EP07862420.2A patent/EP2099451B1/en active Active
- 2007-11-30 PE PE2007001696A patent/PE20081303A1/es not_active Application Discontinuation
- 2007-11-30 WO PCT/US2007/024712 patent/WO2008070011A2/en not_active Ceased
- 2007-11-30 ES ES07862420.2T patent/ES2569477T3/es active Active
- 2007-11-30 RU RU2009125439/15A patent/RU2469717C2/ru not_active IP Right Cessation
- 2007-11-30 US US12/516,656 patent/US8093220B2/en not_active Expired - Fee Related
- 2007-11-30 AU AU2007328281A patent/AU2007328281B2/en not_active Ceased
- 2007-11-30 JP JP2009540242A patent/JP5784274B2/ja not_active Expired - Fee Related
- 2007-11-30 BR BRPI0719746-2A2A patent/BRPI0719746A2/pt not_active IP Right Cessation
- 2007-12-03 CL CL200703467A patent/CL2007003467A1/es unknown
- 2007-12-03 TW TW096145961A patent/TW200831075A/zh unknown
-
2009
- 2009-05-04 ZA ZA200903041A patent/ZA200903041B/xx unknown
- 2009-05-07 IL IL198638A patent/IL198638A/en active IP Right Grant
- 2009-05-29 TN TNP2009000213A patent/TN2009000213A1/fr unknown
- 2009-06-03 GT GT200900148A patent/GT200900148A/es unknown
- 2009-06-10 MA MA31973A patent/MA30982B1/fr unknown
- 2009-06-30 NO NO20092473A patent/NO20092473L/no not_active Application Discontinuation
- 2009-07-03 EC EC2009009483A patent/ECSP099483A/es unknown
-
2013
- 2013-12-26 JP JP2013269307A patent/JP2014097992A/ja active Pending
-
2015
- 2015-07-21 JP JP2015144342A patent/JP2016006070A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000213A1 (en) | Combination | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| MX2011000255A (es) | Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer. | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| EP4371560A3 (en) | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | |
| WO2012143499A3 (de) | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung | |
| IL195142A (en) | Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases | |
| MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
| MX2009012920A (es) | Compuestos heptaciclicos y usos farmaceuticos de los mismos para la prevencion y tratamiento de diabetes y sindrome metabolico. | |
| JO2721B1 (en) | Derivatives of artemisia plant and its preparations and therapeutic applications | |
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| AU2003205768A1 (en) | Methods and compositions for treating hyperproliferative conditions | |
| WO2010121164A3 (en) | 1,4-benzodiazepinone compounds and their use in treating cancer | |
| WO2009062576A3 (en) | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | |
| TW200716224A (en) | Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy | |
| WO2006133707A3 (en) | Anti-cancer combination treatment and kit-of-part | |
| GB201014391D0 (en) | Drug composition and its use in therapy | |
| TW200806293A (en) | Methods of treatment with CETP inhibitors | |
| BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
| MX2013002503A (es) | Combinacion de inhibidores de hdac con farmacos para trombocitopenia. | |
| WO2009151495A3 (en) | Oxazole compounds, compositions and methods of use | |
| WO2009075838A3 (en) | Treatment of menorrhagia with aromatase inhibitor | |
| WO2009015447A3 (en) | Polyacetal-carboxylic acids in the treatment of cancer and auto-immune disorders | |
| UA104144C2 (ru) | Комбинация антагониста с-мет и аминогетероарила для лечения рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |